Fractyl Health Inc., a leading metabolic therapeutics company, has announced a partnership with Bariendo Inc., an innovative obesity care platform. The two companies have signed a non-binding Letter of Intent to explore a collaboration centered on Fractyl's investigational procedure, Revita, as a sustainable solution for post-GLP-1 weight maintenance. This partnership aims to address the increasing demand for endoscopic alternatives that offer a holistic approach to maintaining weight loss after GLP-1 drug discontinuation. The collaboration will focus on preparing for the potential integration of Revita into Bariendo's clinical offerings, pending FDA approval, and will include initiatives such as clinical workflow design and provider education.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。